EWHA, THE FUTURE WE CREATE

EWHA Portal

Ewha W.UEwha W.U

Open Search
Search
Open Mobile Menu

Ewha W.U

Search
nav bar
 
Ewha University

College of Pharmacy

Kang, Soosung Professor

Pharmaceutical Sciences/Division of Pharmacy/Industrial Pharmaceutical Science

강수성 프로필 사진

				
  • Director, Global AI Drug Discovery Center
  • Pharmaceutical Science Building B #314
  • 02-3277-6619
  • Research Interests
Research Record
  • Identification and Biological Evaluation of a Potent and Selective JAK1 Inhibitor for the Treatment of Pulmonary Fibrosis Journal of Medicinal Chemistry, 2023, v.66 no.23, 16342-16363
    SCIE Scopus dColl.
  • Meclizine, a piperazine-derivative antihistamine, binds to dimerized translationally controlled tumor protein and attenuates allergic reactions in a mouse model Biomedicine and Pharmacotherapy, 2023, v.157, 114072
    SCIE Scopus dColl.
  • Tsaokoic Acid: A New Bicyclic Nonene from the Fruits of Amomum tsao-ko with Acetylcholinesterase Inhibitory Activity Molecules (Basel, Switzerland), 2023, v.28 no.6
    SCIE Scopus dColl.
  • 2-Amino-1,3,4-thiadiazoles as Glutaminyl Cyclases Inhibitors Increase Phagocytosis through Modification of CD47-SIRPα Checkpoint ACS Medicinal Chemistry Letters, 2022, v.13 no.9, 1459-1467
    SCIE Scopus dColl.
  • Discovery of potent indazole-based human glutaminyl cyclase (QC) inhibitors as Anti-Alzheimer's disease agents European Journal of Medicinal Chemistry, 2022, v.244, 114837
    SCIE Scopus dColl.
  • Palladium-Catalyzed α-Arylation of Cyclic β-Dicarbonyl Compounds for the Synthesis of CaV1.3 Inhibitors ACS Omega, 2022, v.7 no.16, 14252-14263
    SCIE Scopus dColl.
  • Structure, Function, and Inhibitors of the Mitochondrial Chaperone TRAP1 Journal of Medicinal Chemistry, 2022, v.65 no.24, 16155-16172
    SCIE Scopus dColl.
  • Triphenylphosphonium conjugation to a TRAP1 inhibitor, 2-amino-6-chloro-7,9-dihydro-8H-purin-8-one increases antiproliferative activity Bioorganic Chemistry, 2022, v.126, 105856
    SCIE Scopus dColl.
  • Design and Synthesis of TRAP1 Selective Inhibitors: H-Bonding with Asn171 Residue in TRAP1 Increases Paralog Selectivity ACS MEDICINAL CHEMISTRY LETTERS, 2021, v.12 no.7, 1173-1180
    SCIE Scopus dColl.
  • Discovery and Biological Evaluation of N-Methyl-pyrrolo[2,3-b]pyridine-5-carboxamide Derivatives as JAK1-Selective Inhibitors JOURNAL OF MEDICINAL CHEMISTRY, 2021, v.64 no.2, 958-979
    SCIE Scopus dColl.
  • Mitoquinone Inactivates Mitochondrial Chaperone TRAP1 by Blocking the Client Binding Site JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2021, v.143 no.47, 19684-19696
    SCIE Scopus dColl.
  • A Single Amino Acid Determines the Selectivity and Efficacy of Selective Negative Allosteric Modulators of Ca(v)1.3 L-Type Calcium Channels ACS CHEMICAL BIOLOGY, 2020, v.15 no.9, 2539-2550
    SCIE Scopus dColl.
  • Deciphering Fatty Acid Synthase Inhibition-Triggered Metabolic Flexibility in Prostate Cancer Cells through Untargeted Metabolomics Cells, 2020, v.9 no.11, 0
    SCIE Scopus dColl.
  • Development of pyrazolo[3,4-d]pyrimidine-6-amine-based TRAP1 inhibitors that demonstrate in vivo anticancer activity in mouse xenograft models Bioorganic Chemistry, 2020, v.101, 103901
    SCIE Scopus dColl.
  • Discovery of 2-((4-resorcinolyl)-5-aryl-1,2,3-triazol-1-yl)acetates as potent Hsp90 inhibitors with selectivity over TRAP1 BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2020, v.30 no.2, 126809
    SCIE Scopus dColl.
  • Physiological involvement of presynaptic L-type voltage-dependent calcium channels in GABA release of cerebellar molecular layer interneurons JOURNAL OF NEUROCHEMISTRY, 2020, v.155 no.4, 390-402
    SCIE Scopus dColl.
  • Practical direct synthesis of: N -aryl-substituted azacycles from N -alkyl protected arylamines using TiCl4and DBU Organic and Biomolecular Chemistry, 2020, v.18 no.26, 5008-5016
    SCIE Scopus dColl.
  • Casein kinase-1 gamma 1 and 3 stimulate tumor necrosis factor-induced necroptosis through RIPK3 CELL DEATH & DISEASE, 2019, v.10, 923
    SCIE Scopus dColl.
  • Metal-Free Synthesis of N-Aryl-Substituted Azacycles from Cyclic Ethers Using POCI3 JOURNAL OF ORGANIC CHEMISTRY, 2019, v.84 no.11, 6689-6696
    SCIE Scopus dColl.
  • Synthesis and evaluation of novel potent TSPO PET ligands with 2-phenylpyrazolo [1,5-a]pyrimidin-3-yl acetamide BIOORGANIC & MEDICINAL CHEMISTRY, 2019, v.27 no.18, 4069-4080
    SCIE Scopus dColl.
  • CF3-Substituted Mollugin 2-(4-Morpholinyl)-ethyl ester as a Potential Anti-inflammatory Agent with Improved Aqueous Solubility and Metabolic Stability MOLECULES, 2018, v.23 no.8, 2030
    SCIE Scopus dColl.
  • Convenient metal-free direct oxidative amidation of aldehyde using dibromoisocyanuric acid under mild conditions TETRAHEDRON LETTERS, 2018, v.59 no.39, 3541-3546
    SCIE Scopus dColl.
  • Evolution of In Silico Strategies for Protein-Protein Interaction Drug Discovery MOLECULES, 2018, v.23 no.8, 1963
    SCIE Scopus dColl.
  • Exploring G Protein-Coupled Receptors (GPCRs) Ligand Space via Cheminformatics Approaches: Impact on Rational Drug Design FRONTIERS IN PHARMACOLOGY, 2018, v.9
    SCIE Scopus dColl.
  • Facile direct synthesis of unsymmetrical ureas from N-Alloc-, N-Cbz-, and N-Boc-protected amines using DABAL-Me-3 TETRAHEDRON, 2018, v.74 no.30, 4036-4046
    SCIE Scopus dColl.
  • Hypervalent Iodine-Mediated Alkene Functionalization: Oxazoline and Thiazoline Synthesis via Inter-/Intramolecular Aminohydroxylation and Thioamination ADVANCED SYNTHESIS & CATALYSIS, 2018, v.360 no.4, 779-783
    SCIE Scopus dColl.
  • Paralog Specificity Determines Subcellular Distribution, Action Mechanism, and Anticancer Activity of TRAP1 Inhibitors JOURNAL OF MEDICINAL CHEMISTRY, 2017, v.60 no.17
    SCIE Scopus dColl.
  • Electrostatic Control of Isoform Selective Inhibitor Binding in Nitric Oxide Synthase BIOCHEMISTRY, 2016, v.55 no.26, 3702-3707
    SCIE Scopus dColl.
  • Regulation of aldosterone secretion by Ca(v)1.3 SCIENTIFIC REPORTS, 2016, v.6, 24697
    SCIE Scopus dColl.
  • 2-Aminopyridines with a Truncated Side Chain To Improve Human Neuronal Nitric Oxide Synthase Inhibitory Potency and Selectivity JOURNAL OF MEDICINAL CHEMISTRY, 2015, v.58 no.14, 5548-5560
    SCIE Scopus dColl.
  • Inhibitor Bound Crystal Structures of Bacterial Nitric Oxide Synthase BIOCHEMISTRY, 2015, v.54 no.26, 4075-4082
    SCIE Scopus dColl.
  • Nitric Oxide Synthase as a Target for Methicillin-Resistant Staphylococcus aureus CHEMISTRY & BIOLOGY, 2015, v.22 no.6, 785-792
    SCIE Scopus dColl.
  • Phenyl Ether- and Aniline-Containing 2-Aminoquinolines as Potent and Selective Inhibitors of Neuronal Nitric Oxide Synthase JOURNAL OF MEDICINAL CHEMISTRY, 2015, v.58 no.21, 8694-8712
    SCIE Scopus dColl.
  • Serotonergic signalling suppresses ataxin 3 aggregation and neurotoxicity in animal models of Machado-Joseph disease BRAIN, 2015, v.138
    SCIE Scopus dColl.
  • Structure-Based Design of Bacterial Nitric Oxide Synthase Inhibitors JOURNAL OF MEDICINAL CHEMISTRY, 2015, v.58 no.2, 994-1004
    SCIE Scopus dColl.
  • Development of nitric oxide synthase inhibitors for neurodegeneration and neuropathic pain CHEMICAL SOCIETY REVIEWS, 2014, v.43 no.19, 6814-6838
    SCIE Scopus dColl.
  • The Mobility of a Conserved Tyrosine Residue Controls Isoform-Dependent Enzyme-Inhibitor Interactions in Nitric Oxide Synthases BIOCHEMISTRY, 2014, v.53 no.32, 5272-5279
    SCIE Scopus dColl.
  • [학술지논문] Identification and Biological Evaluation of a Potent and Selective JAK1 Inhibitor for the Treatment of Pulmonary Fibrosis JOURNAL OF MEDICINAL CHEMISTRY, 2023, v.66 no.23 , 16342-16363
    SCIE
  • [학술지논문] Meclizine, a piperazine-derivative antihistamine, binds to dimerized translationally controlled tumor protein and attenuates allergic reactions in a mouse model BIOMEDICINE & PHARMACOTHERAPY, 2023, v.157 no.157 , 114072-114072
    SCIE
  • [학술지논문] 2-Amino-1,3,4-thiadiazoles as Glutaminyl Cyclases Inhibitors Increase Phagocytosis through Modification of CD47-SIRP alpha Checkpoint ACS MEDICINAL CHEMISTRY LETTERS, 2022, v.13 no.9 , 1459-1467
    SCIE
  • [학술지논문] Discovery of potent indazole-based human glutaminyl cyclase (QC) inhibitors as Anti-Alzheimer's disease agents EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, v.244 no.0 , 114837-114837
    SCI
  • [학술지논문] Palladium-Catalyzed alpha-Arylation of Cyclic beta-Dicarbonyl Compounds for the Synthesis of Ca(V)1.3 Inhibitors ACS OMEGA, 2022, v.7 no.16 , 14252-14263
    SCIE
  • [학술지논문] Structure, Function, and Inhibitors of the Mitochondrial Chaperone TRAP1 JOURNAL OF MEDICINAL CHEMISTRY, 2022, v.65 no.24 , 16155-16172
    SCI
  • [학술지논문] Triphenylphosphonium conjugation to a TRAP1 inhibitor, 2-amino-6--chloro-7,9-dihydro-8H-purin-8-one increases antiproliferative activity BIOORGANIC CHEMISTRY, 2022, v.126 no.126 , 105856-105856
    SCI
  • [학술지논문] Design and Synthesis of TRAP1 Selective Inhibitors: H-Bonding with Asn171 Residue in TRAP1 Increases Paralog Selectivity ACS MEDICINAL CHEMISTRY LETTERS, 2021, v.12 no.7 , 1173-1180
    SCIE
  • [학술지논문] Discovery and Biological Evaluation of N-Methyl-pyrrolo[2,3-b]pyridine-5-carboxamide Derivatives as JAK1-Selective Inhibitors JOURNAL OF MEDICINAL CHEMISTRY, 2021, v.64 no.2 , 958-979
    SCI
  • [학술지논문] A Single Amino Acid Determines the Selectivity and Efficacy of Selective Negative Allosteric Modulators of Ca(v)1.3 L-Type Calcium Channels ACS CHEMICAL BIOLOGY, 2020, v.15 no.9 , 2539-2550
    SCIE
  • [학술지논문] Deciphering Fatty Acid Synthase Inhibition-Triggered Metabolic Flexibility in Prostate Cancer Cells through Untargeted Metabolomics CELLS, 2020, v.9 no.11 , 2447-2447
    SCIE
  • [학술지논문] Development of pyrazolo[3,4-d]pyrimidine-6-amine-based TRAP1 inhibitors that demonstrate in vivo anticancer activity in mouse xenograft models BIOORGANIC CHEMISTRY, 2020, v.101 no.0 , 103901-103901
    SCI
  • [학술지논문] Discovery of 2-((4-resorcinolyl)-5-aryl-1,2,3-triazol-1-yl)acetates as potent Hsp90 inhibitors with selectivity over TRAP1 BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2020, v.30 no.2 , 126809-126809
    SCI
  • [학술지논문] Physiological involvement of presynaptic L-type voltage-dependent calcium channels in GABA release of cerebellar molecular layer interneurons JOURNAL OF NEUROCHEMISTRY, 2020, v.155 no.4 , 390-402
    SCI
  • [학술지논문] Practical direct synthesis of N-aryl-substituted azacycles from N-alkyl protected arylamines using TiCl4 and DBU ORGANIC & BIOMOLECULAR CHEMISTRY, 2020, v.18 no.26 , 5008-5016
    SCI
  • [학술지논문] Casein kinase-1 gamma 1 and 3 stimulate tumor necrosis factor-induced necroptosis through RIPK3 CELL DEATH & DISEASE, 2019, v.10 no.0 , 923-923
    SCIE
  • [학술지논문] Metal-Free Synthesis of N-Aryl-Substituted Azacycles from Cyclic Ethers Using POCI3 JOURNAL OF ORGANIC CHEMISTRY, 2019, v.84 no.11 , 6689-6696
    SCI
  • [학술지논문] Synthesis and evaluation of novel potent TSPO PET ligands with 2-phenylpyrazolo [1,5-a]pyrimidin-3-yl acetamide BIOORGANIC & MEDICINAL CHEMISTRY, 2019, v.27 no.18 , 4069-4080
    SCI
  • [지적재산권] JAK 저해제 화합물, 및 이를 포함하는 의약 조성물 Domestic : Patent , Application
  • [지적재산권] JAK 저해제 화합물, 및 이의 제조방법 Domestic : Patent , Registration , 제10-2034538호, 2019
Courses
  • 2023-2nd

  • 2023-1st

  • 2022-2nd

    • Pharmaceutical Synthesis Ⅲ

      • Subject No 33948Class No 01
      • 4Year ( 1.5Credit , 1.5Hour) Tue 4~4 (PHM-A100-1)
      • Major Requisite
    • Pharmaceutical Synthesis Ⅲ

      • Subject No 33948Class No 02
      • 4Year ( 1.5Credit , 1.5Hour) Tue 3~3 (PHM-A100-1)
      • Major Requisite
    • Pharmaceutical Synthesis Ⅲ

      • Subject No 33948Class No 03
      • 4Year ( 1.5Credit , 1.5Hour) Thu 5~5 (PHM-A100-1)
      • Major Requisite
    • Pharmaceutical Synthesis Ⅲ

      • Subject No 33948Class No 04
      • 4Year ( 1.5Credit , 1.5Hour) Thu 5~5 (PHM-A100-1)
      • Major Requisite
    • Pharmaceutical Experiment Laboratory IV

      • Subject No 37127Class No 01
      • 4Year ( 1.5Credit , 3Hour) Mon 6~7 (PHM-A309)
      • Major Requisite
    • Pharmaceutical Experiment Laboratory IV

      • Subject No 37127Class No 02
      • 4Year ( 1.5Credit , 3Hour) Tue 6~7 (PHM-A309)
      • Major Requisite
    • Pharmaceutical Experiment Laboratory IV

      • Subject No 37127Class No 03
      • 4Year ( 1.5Credit , 3Hour) Wed 6~7 (PHM-A309)
      • Major Requisite
    • Advanced Pharmacy Practice and Research I

      • Subject No 37154Class No 01
      • 6Year ( 4Credit , 200Hour)
      • Major Requisite
    • Honors research

    • Advanced Medicinal Chemistry II

      • Subject No G16905Class No 01
      • Year ( 3Credit , 3Hour) Wed 2~3 (PHM-)
    • Understanding and application of Bioinformatics and Chemoinformatics

      • Subject No G18091Class No 01
      • Year ( 3Credit , 3Hour) Mon 2~3 (PHM-)
  • 2022-1st

    • Pharmaceutical Chemistry

      • Subject No 22576Class No 01
      • 3Year ( 3Credit , 3Hour) Tue 2~2 , Thu 3~3
    • Pharmaceutical Chemistry

      • Subject No 22576Class No 02
      • 3Year ( 3Credit , 3Hour) Tue 3~3 , Thu 4~4
    • Pharmaceutical Synthesis Ⅱ

      • Subject No 33947Class No 01
      • 4Year ( 3Credit , 3Hour) Tue 5~5 (PHM-A400) , Wed 3~3 (PHM-A400)
      • Major Requisite
    • Pharmaceutical Synthesis Ⅱ

      • Subject No 33947Class No 02
      • 4Year ( 3Credit , 3Hour) Mon 4~4 (PHM-A400) , Wed 4~4 (PHM-A400)
      • Major Requisite
    • Pharmaceutical Synthesis Ⅱ

      • Subject No 33947Class No 03
      • 4Year ( 3Credit , 3Hour) Mon 3~3 (PHM-A100-1) , Thu 6~6 (PHM-A400)
      • Major Requisite
    • Pharmaceutical Synthesis Ⅱ

      • Subject No 33947Class No 04
      • 4Year ( 3Credit , 3Hour) Mon 3~3 (PHM-A100-1) , Thu 6~6 (PHM-A400)
      • Major Requisite
    • Pharmaceutical Experiment Laboratory IV

      • Subject No 37127Class No 01
      • 4Year ( 1.5Credit , 3Hour) Tue 6~7 (PHM-A309)
      • Major Requisite
    • Pharmaceutical Experiment Laboratory IV

      • Subject No 37127Class No 02
      • 4Year ( 1.5Credit , 3Hour) Mon 6~7 (PHM-A309)
      • Major Requisite
    • Pharmaceutical Experiment Laboratory IV

      • Subject No 37127Class No 03
      • 4Year ( 1.5Credit , 3Hour) Wed 6~7 (PHM-A309)
      • Major Requisite
    • Pharmaceutical Experiment Laboratory IV

      • Subject No 37127Class No 04
      • 4Year ( 1.5Credit , 3Hour) Wed 6~7 (PHM-A309)
      • Major Requisite
    • Advanced Medicinal Chemistry I

      • Subject No G16861Class No 01
      • Year ( 3Credit , 3Hour) Fri 5~6 (PHM-)
  • 2021-2nd

    • Pharmaceutical Synthesis Ⅲ

      • Subject No 33948Class No 01
      • 4Year ( 1.5Credit , 1.5Hour) Tue 4~4
      • Major Requisite
    • Pharmaceutical Synthesis Ⅲ

      • Subject No 33948Class No 02
      • 4Year ( 1.5Credit , 1.5Hour) Thu 2~2
      • Major Requisite
    • Pharmaceutical Synthesis Ⅲ

      • Subject No 33948Class No 03
      • 4Year ( 1.5Credit , 1.5Hour) Thu 5~5
      • Major Requisite
    • Pharmaceutical Synthesis Ⅲ

      • Subject No 33948Class No 04
      • 4Year ( 1.5Credit , 1.5Hour) Thu 5~5
      • Major Requisite
    • Pharmaceutical Experiment Laboratory IV

      • Subject No 37127Class No 01
      • 4Year ( 1.5Credit , 3Hour) Mon 6~7 (PHM-A309)
      • Major Requisite
    • Pharmaceutical Experiment Laboratory IV

      • Subject No 37127Class No 02
      • 4Year ( 1.5Credit , 3Hour) Tue 6~7 (PHM-A309)
      • Major Requisite
    • Pharmaceutical Experiment Laboratory IV

      • Subject No 37127Class No 03
      • 4Year ( 1.5Credit , 3Hour) Wed 6~7 (PHM-A309)
      • Major Requisite
    • Advanced Pharmacy Practice and Research I

      • Subject No 37154Class No 01
      • 6Year ( 4Credit
      • Major Requisite
    • Honors research

      • Subject No 37803Class No 01
      • 4Year ( 1Credit , 1Hour)
    • Advanced Medicinal Chemistry II

      • Subject No G16905Class No 01
      • Year ( 3Credit , 3Hour) Tue 2~3 (PHM-)
  • 2021-1st

    • Pharmaceutical Chemistry

      • Subject No 22576Class No 01
      • 3Year ( 3Credit , 3Hour) Tue 4~4 , Thu 6~6
    • Pharmaceutical Chemistry

      • Subject No 22576Class No 02
      • 3Year ( 3Credit , 3Hour) Mon 3~3 , Thu 5~5
    • Pharmaceutical Chemistry

      • Subject No 22576Class No 03
      • 3Year ( 3Credit , 3Hour) Mon 3~3 , Thu 5~5
    • Pharmaceutical Synthesis Ⅱ

      • Subject No 33947Class No 01
      • 4Year ( 3Credit , 3Hour) Tue 2~2 , Fri 3~3
      • Major Requisite
    • Pharmaceutical Synthesis Ⅱ

      • Subject No 33947Class No 02
      • 4Year ( 3Credit , 3Hour) Wed 4~4 , Fri 4~4
      • Major Requisite
    • Pharmaceutical Synthesis Ⅱ

      • Subject No 33947Class No 03
      • 4Year ( 3Credit , 3Hour) Mon 4~4 , Thu 4~4
      • Major Requisite
    • Pharmaceutical Synthesis Ⅱ

      • Subject No 33947Class No 04
      • 4Year ( 3Credit , 3Hour) Mon 4~4 , Thu 4~4
      • Major Requisite
    • Pharmaceutical Experiment Laboratory IV

      • Subject No 37127Class No 01
      • 4Year ( 1.5Credit , 3Hour) Mon 6~7 (PHM-A309)
      • Major Requisite
    • Pharmaceutical Experiment Laboratory IV

      • Subject No 37127Class No 02
      • 4Year ( 1.5Credit , 3Hour) Tue 6~7 (PHM-A309)
      • Major Requisite
    • Pharmaceutical Experiment Laboratory IV

      • Subject No 37127Class No 03
      • 4Year ( 1.5Credit , 3Hour) Wed 6~7 (PHM-A309)
      • Major Requisite
    • Pharmaceutical Experiment Laboratory IV

      • Subject No 37127Class No 04
      • 4Year ( 1.5Credit , 3Hour) Wed 6~7 (PHM-A309)
      • Major Requisite
Academic Background

Purdue University Ph.D.(Chemistry)